



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61K 39/00* (2006.01)
C07K 14/725 (2006.01) *A61P 35/00* (2006.01)
C12N 5/0783 (2010.01) *C07K 14/705* (2006.01)

(21) International Application Number:

PCT/US2022/079216

(22) International Filing Date:

03 November 2022 (03.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/128578

04 November 2021 (04.11.2021) CN
 63/275,471 04 November 2021 (04.11.2021) US

(71) Applicants: **JANSSEN BIOTECH, INC.** [US/US];
 800/850 Ridgeview Drive, Horsham, PA 19044 (US).
NANJING LEGEND BIOTECH CO., LTD. [CN/CN];
 No. 6 Building Of Nanjing Life Science Town, No. 568
 Longmian Avenue, Jiangning District, Nanjing, Jiangsu,
 211100 (CN).

(72) Inventors: **AKRAM, Muhammad**; c/o Legend Biotech,
 2101 Cottontail Lane, Somerset, NJ 08873 (US). **DEBRA-
 GANCA, Kevin**; 920 US Route 202, Raritan, NJ 08869
 (US). **FAN, Xiaohu**; 1067 Armitage Crescent SW, Ed-
 monton, AB T6W 0K3 (CA). **GENG, Dong**; c/o Legend
 Biotech, 2101 Cottontail Lane, Somerset, NJ 08873 (US).
NESHEIWAT, Tonia; c/o Legend Biotech, 2101 Cotton-
 tail Lane, Somerset, NJ 08873 (US). **PACAUD, Lida**; c/o

Legend Biotech, 2101 Cottontail Lane, Somerset, NJ 08873
 (US). **SCHecter, Jordan**; 920 Us Route 202, Raritan,
 NJ 08869 (US). **VARSOS, Helen**; 1400 McKean Road,
 Spring House, PA 19477 (US). **ZUDAIRE, Enrique**; 1400
 McKean Road, Spring House, PA 19477 (US).

(74) Agent: **LIANG, Bing** et al.; Jones Day, 250 Vesey Street,
 New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
 KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
 LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
 RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
 ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, CV,
 GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
 SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA




Figure 1

(57) Abstract: Provided herein are methods of treating a subject who has multiple myeloma and has received prior treatment and has limited treatment options. Infusions of chimeric antigen receptor (CAR)-T cells comprising an anti-BCMA CAR comprising a polypeptide are administered to the subject. In certain embodiments, the dose of CAR-T cells administered to the subject is from 1.0×10^5 to 5.0×10^6 of CAR-T cells per kilogram of the subject's mass. The method of treatment is effective in obtaining and maintaining minimal residual disease negativity status, as well as other beneficial clinical outcomes related to efficacy and safety.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*